# Adding Aprepitant to a Multimodal Strategy for the Prevention of Postoperative Nausea and Vomiting in High-risk Outpatient Surgical Patients

> **NCT07248280** · PHASE3 · RECRUITING · sponsor: **Centre hospitalier de l'Université de Montréal (CHUM)** · enrollment: 260 (estimated)

## Conditions studied

- Nausea and Vomiting, Postoperative
- Prevention

## Interventions

- **DRUG:** Aprepitant 40mg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07248280
- **Lead sponsor:** Centre hospitalier de l'Université de Montréal (CHUM)
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-02-27
- **Primary completion:** 2026-07-01
- **Final completion:** 2027-01-01
- **Target enrollment:** 260 (ESTIMATED)
- **Last updated:** 2026-03-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07248280

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07248280, "Adding Aprepitant to a Multimodal Strategy for the Prevention of Postoperative Nausea and Vomiting in High-risk Outpatient Surgical Patients". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT07248280. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*